prikaz prve stranice dokumenta Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients
  Preuzmi
PDF 5.37 MB
Znanstveni rad - Izvorni znanstveni rad
Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients
Croatian Medical Journal, 63 (2022), 2; 126-140. https://doi.org/10.3325/cmj.2022.63.126
Ramić, Snježana; Paić, Frane; Smajlbegović, Velda; Perić Balja, Melita; Hiršl, Lea; Marton, Ingrid; Knežević, Fabijan

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Ramić, S., Paić, F., Smajlbegović, V., Perić Balja, M., Hiršl, L., Marton, I. i Knežević, F. (2022). Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients. Croatian Medical Journal, 63. (2), 126-140. doi: 10.3325/cmj.2022.63.126

Ramić, Snježana, et al. "Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients." Croatian Medical Journal, vol. 63, br. 2, 2022, str. 126-140. https://doi.org/10.3325/cmj.2022.63.126

Ramić, Snježana, Frane Paić, Velda Smajlbegović, Melita Perić Balja, Lea Hiršl, Ingrid Marton i Fabijan Knežević. "Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients." Croatian Medical Journal 63, br. 2 (2022): 126-140. https://doi.org/10.3325/cmj.2022.63.126

Ramić, S., et al. (2022) 'Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients', Croatian Medical Journal, 63(2), str. 126-140. doi: 10.3325/cmj.2022.63.126

Ramić S, Paić F, Smajlbegović V, Perić Balja M, Hiršl L, Marton I, i sur.. Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients. Croatian Medical Journal [Internet]. 30.04.2022. [pristupljeno 28.11.2024.];63(2):126-140. doi: 10.3325/cmj.2022.63.126

S. Ramić, et al., "Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients", Croatian Medical Journal, vol. 63, br. 2, str. 126-140, Travanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:519799. [Citirano: 28.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:519799
Podaci o radu
Naslov (engleski)Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients
AutorSnježana Ramić
AutorFrane Paić
AutorVelda Smajlbegović
AutorMelita Perić Balja
AutorLea Hiršl
AutorIngrid Marton
AutorFabijan Knežević
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA MEDICINSKU BIOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Medicinska biokemija
Sažetak (engleski)
Aim: To determine the predictive value of phosphorylated human epidermal growth factor receptor 2 (pHER2Y1248) status in breast cancer (BC) patients undergoing trastuzumab-based adjuvant therapy. ----- Methods: Immunohistochemical status of pHER2Y1248, EGFR/HER1, HER3, and HER4 was determined in 124 consecutive HER2-positive BC patients (median age [range]=57 years [49.0-64.0]) treated at the University Hospital for Tumors, Zagreb, between 2008 and 2011. The median follow-up was 84 months (60.0-84.0). Prognostic factors of disease free survival (DFS) rate were evaluated with Kaplan-Meier/log-rank test and Cox regression analysis. ----- Results: pHER2Y1248, HER1, HER3, and HER4 were expressed in 66.1%, 9.7%, 70.2%, and 71.0% of patients, respectively. Disease progression (DP) was observed in 17.1% of pHER2Y1248-positive and 47.6% of pHER2Y1248-negative BCs (P=0.001). Kaplan-Meier analysis showed a worse five-year DFS in pHER2Y1248-negative patients who were older than 60 years (P<0.001) and had positive lymph node status (P<0.001); tumor size >2.0 cm (P<0.001); higher histological grade (P<0.001); HER2E intrinsic subtype (P<0.001), negative hormone receptors (P<0.001); negative HER1 status (P<0.001), positive HER3 (P=0.002); and/or positive HER4 (P=0.002) status. The only negative prognostic factor for five-year DFS in multivariate Cox regression analysis was pHER2Y1248-negative (hazard ratio [HR] 3.6, 95% confidence interval [CI] 1.8-7.2, P<0.001) and lymph node-positive status (HR 3.6, 95% CI 1.3-9.8, P=0.014). ----- Conclusion: pHER2Y1248 predicts sensitivity to trastuzumab and a better five-year DFS regardless of any other prognostic parameter. In HER2-positive BC patients. Non-phosphorylated HER2Y1248 is a strong predictor of trastuzumab resistance and a poor DFS.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCroatian Medical Journal
Brojčani podacivol. 63, br. 2, str. 126-140
p-ISSN0353-9504
e-ISSN1332-8166
DOIhttps://doi.org/10.3325/cmj.2022.63.126
URN:NBNurn:nbn:hr:105:519799
Datum objave publikacije2022-04-30
URL dokumentahttp://www.cmj.hr/2022/63/2/35505646.htm
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2022-05-20 10:14:43